IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter
Tarsier Pharma Ltd.
Tarsier Pharma is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet need in blinding diseases of the eye with underlying inflammatory pathologies.
Our dazdotuftide platform technology is a bio-inspired immunomodulator, designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops (TRS01) and intravitreal injections (TRS02).
The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Key valuation ratios and metrics
Balance sheet strength and liquidity
Margins and return on capital
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| F-1/A | Jun 16, 2026 | [Amend] Registration statement for certain foreign private issuers |
| F-1/A | Jun 8, 2026 | [Amend] Registration statement for certain foreign private issuers |
| FWP | May 18, 2026 | Free Writing Prospectus |
| F-1/A | May 18, 2026 | [Amend] Registration statement for certain foreign private issuers |
| F-1 | Apr 21, 2026 | Registration statement for certain foreign private issuers |
| DRS/A | Mar 31, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Feb 24, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Dec 29, 2025 | [Cover] Draft Registration Statement |
Contact and headquarters details
Key executives and officers
Daphne Haim-Langford, Ph.D.
Chief Executive Officer and Chairperson of the Board
Arie Ganot, CPA
Chief Financial Officer
Zohar Milman, M.Sc.
Chief Operating Officer
Ron Neumann, M.D.
Chief Medical Officer
Susan Benton
Director
Sascha Bucher
Director
Atul Raut
Director

Issue Size
$45.00M
Price Range
$8.00 - $10.00
Shares
28.74M o/s · 5M offered
Probable listing
Jul 15, 2026
Sector
Healthcare